ReviewPurinergic signalling2026
ATP is not always pro-inflammatory: rethinking purinergic signalling in cancer and autoimmunity.
Review in Purinergic signalling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular adenosine 5'-triphosphate (ATP) has been recognized for many years as a prototypical danger signal that promotes inflammation primarily through activation of purinergic receptors, particularly P2X7. This framework has had a massive influence on how immunology, cancer biology, and autoimmunity are now conceived. Nonetheless, increasing experimental and clinical observations do not support the simple, unidimensional model of ATP as a pro-inflammatory mediator; instead, they suggest that, depending on the concentration, timing, receptor context, and cellular status, ATP may have strong immunosuppressive/tolerogenic effects. Prolonged ATP signalling has increasingly been implicated in immune effector fatigue during chronic inflammation, cancer, and sustained infection, which dampens down immune stimulation rather than augmenting it. In this narrative review, we critically examine published evidence supporting the context-dependent effects of extracellular ATP and discuss how receptor expression, ATP concentration, exposure duration, nucleotide metabolism, and cellular state may shape immune responses in cancer and autoimmune disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.